Natco Pharma has unveiled a rights issue to raise up to Rs 1,279.4 crore at an issue price of Rs 750 per share. The company will offer 2 rights shares for every 21 equity shares held by investors. The proceeds are primarily earmarked for debt repayment, which is expected to strengthen the company’s balance sheet. The issue opens on October 12, 2026, with a record date of October 1, 2026.
Natco Pharma Announces Rs 1,279 Crore Rights Issue
Issue Size: Rs 1,279.4 crore at an issue price of Rs 750 per share.
Debt Repayment Allocation: Rs 810.5 crore to be utilized from proceeds.
Reader Takeaway: The rights issue strengthens the balance sheet through significant debt reduction, though R&D and acquisition success remain execution-dependent.
What just happened
Natco Pharma has officially announced a rights issue of up to 17,058,082 equity shares. The issue is priced at Rs 750 per share, which includes a face value of Rs 2 and a premium of Rs 748. Shareholders will receive an entitlement of 2 rights shares for every 21 equity shares held as of the record date, October 1, 2026. The company’s Fund-Raising Committee approved the Letter of Offer on September 28, 2026.
Why this matters
The primary objective of this fundraising is financial consolidation. Natco Pharma reported consolidated debt of Rs 954.3 crore as of August 31, 2026. By allocating Rs 810.5 crore toward debt repayment, the company intends to significantly improve its debt-to-equity ratio and enhance its debt service coverage capabilities. The remaining funds are designated for R&D (Rs 110 crore) and inorganic growth initiatives.
The backstory
As of late 2026, Natco Pharma is leveraging this capital raise to optimize its capital structure. The company has appointed CRISIL Ratings Limited as the monitoring agency to ensure transparency in the utilization of the gross proceeds. Stringent limits have been placed on general corporate and inorganic growth usage, capped at 35% of the total issue size.
Important dates for investors
- Record Date: October 1, 2026
- Issue Opening: October 12, 2026
- Renunciation Deadline: October 16, 2026
- Issue Closing: October 22, 2026
- Listing Date: October 27, 2026
Risks to watch
The effectiveness of the R&D and inorganic growth plans depends heavily on management's ability to identify suitable acquisition targets and successfully integrate them. Investors should monitor how effectively the company pivots toward growth once the debt burden is alleviated.